In addition, evidence has determined that the stable attachment of nimotuzumab requires bivalent binding, so nimotuzumab selectively binds to tumor cells expressing moderate to high EGFR levels, thereby protecting healthy cells with low levels of EGFR, and thus severe skin toxicity does not occur.32, 44. The gene discussed is EGFR; the disease is neoplasm.